2020
DOI: 10.1002/cti2.1172
|View full text |Cite
|
Sign up to set email alerts
|

p.P476S mutation of RBPJL inhibits the efficacy of anti‐PD‐1 therapy in oesophageal squamous cell carcinoma by blunting T‐cell responses

Abstract: Objectives. Anti-PD-1 immune checkpoint blockade represents the onset of a new era in cancer immunotherapy. However, robust predictors are necessary for screening patients with immune checkpoint-responsive oesophageal squamous cell carcinoma (ESCC). Methods. We obtained biopsy samples from an ESCC patient with mixed responses. The expression of CD4, CD8, CD68, PD-L1, RBPJL and IL-16 was analysed by immunohistochemistry, and the correlation with prognostic value was obtained from the GEPIA portal. T-cell functi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 55 publications
0
1
0
Order By: Relevance
“…NB tissue samples and mice tumor samples were fixed and embedded for IHC staining as previously described. 51 After Five representative fields of each section were captured and analyzed. The average positive ratio was defined by the symbol and color.…”
Section: Ihc and Immunofluorescencementioning
confidence: 99%
“…NB tissue samples and mice tumor samples were fixed and embedded for IHC staining as previously described. 51 After Five representative fields of each section were captured and analyzed. The average positive ratio was defined by the symbol and color.…”
Section: Ihc and Immunofluorescencementioning
confidence: 99%